Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

Langerhans cell histiocytosis (LCH) often has a recurrent and refractory course despite multiagent treatment modalities. Common relapse treatments include intense or prolonged cytotoxic chemotherapy regimens. There are a few prior reports that the nonsteroidal anti-inflammatory drug indomethacin demonstrated activity against bone LCH. Here we report indomethacin as a successful treatment for a case of chronic skin LCH that failed multiple prior chemotherapy regimens. This experience supports the need for trials to investigate indomethacin as a treatment for LCH both in the relapsed or refractory setting as well as potential combination or maintenance therapy in newly diagnosed patients.


Aditi Dhir, David R Kelly, Raymond G Watts, Matthew A Kutny. Recurrent Skin Langerhan Cell Histiocytosis Successfully Treated With Indomethacin Monotherapy. Journal of pediatric hematology/oncology. 2020 Nov;42(8):e795-e797

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 30951019

View Full Text